SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John S. Baker who wrote (370)8/15/1998 10:03:00 AM
From: muddphudd  Read Replies (2) of 586
 
Wow! Its been dead here for a while.

Copied this from the Yahoo thread:

"How are our prospects affected by the news this week that an FDA advisory panel had recommended approval of Hoechst's Arava drug, a new therapy for the treatment of rheumatoid arthritis. It provides relief from the disease's symptoms and retards the structural damage that the disease causes. The panel also recommended to the FDA that the drug's label be expanded to include improve to the sufferer's physical functioning.The NDA was filed on March 10 and the FDA designated the drug for priority review."

Thoughts??
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News